论文部分内容阅读
2012年12月14日,FDA批准ponatinib hydrochloride(商品名为Iclusig)在美国上市,该药由Ariad制药公司开发,该药为片剂,用于慢性髓细胞白血病(CML)和费城染色体阳性急性淋巴细胞白血病(Ph+ALL)的治疗。Ponatinib hydrochloride的中文名称:3-(咪唑并[1,2-b]哒嗪-3-基乙炔基)-4-甲基-N-{4-[(4-甲基哌嗪-1-基)甲基]-
The FDA approved ponatinib hydrochloride (Iclusig) marketed in the United States on December 14, 2012. The drug was developed by Ariad Pharmaceuticals as a tablet for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic Treatment of cell leukemia (Ph + ALL). Ponatinib hydrochloride Chinese name: 3- (imidazo [1,2-b] pyridazin-3-ylethynyl) -4- methyl-N- {4- [ )methyl]-